Activating mutations in the KRAS gene can be found in 35% of all lung cancers and in up to 93% of NSCLC cases in smokers27,28 These mutations drive tumor development and disease progression29–32, as meta-analysis in patients with NSCLC has shown that KRAS mutations are associated with poor prognosis and worse overall survival compared to those without KRAS mutations33,34. Here, KRAS is linked to lung cancer.